Genfit: GENFIT Launches a Phase 2 Trial Evaluating Elafibranor on Hepatic Lipid Composition for NAFL
GENFIT Launches a Phase 2 Trial Evaluating Elafibranor on Hepatic Lipid Composition for NAFL Phase 2 study to evaluate the effect of a 6-week, once daily treatment of elafibranor (120mg) vs. placebo ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback